Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (39)	10/28/2014 9:48:48 PM
From: fitzdad55	Read Replies (1) \| Respond to of 136

An interesting move by Dahiyat. Because the ph2a trial for XmaB5871 was blinded we don't know the results yet. (Dahiyat stated results will be disclosed end of year.) It does seem to mark a more intensive focus on mAb therapies for diseases with unmet needs. RA is certainly a crowded and competitive space and this may prove to be a very smart move for Xencor in the longer term. Of course, I'm still wondering what the Ph2a results will reveal when they are announced.

To: scaram(o)uche who wrote (39)	10/29/2014 12:27:16 PM
From: tuck	Read Replies (1) \| Respond to of 136

This has to be one of the most boring trading stocks in biotech. I haven't looked but the beta seems absurdly low, just from watching it over the last few months. A 1% wiggle on this news, which is an average day here. Just kinda strange. Anyhow, I guess I agree with Fitzdad, this could be a smart move. A mere nuance for Amgen, which now sort of has a fuzzy option with no price (presumably there is some definition of what a good faith negotiation is before Xencor can talk to others). If the data are good in RA, I would think Xencor would simply out-license that indication per the new contract. So RA still matters, and I still have the concern. Apparently, Xencor & Amgen do, too, a little bit. Cheers, Tuck